Share. Connect. Create. Grow. · Socialiya
Lilly pens $2.3B deal for next-gen JAK inhibitor biotech Ajax

Eli Lilly's run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma n...

BUSINESS NEWS April 27, 2026

Lilly pens $2.3B deal for next-gen JAK inhibitor biotech Ajax

Eli Lilly's run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax Therapeutics for its clinical-stage...

12 views 0 likes 0 comments
Share:
Eli Lilly's run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax Therapeutics for its clinical-stage...

Author: Fierce Biotech

Read Original Article

Related News

Advertisement
socialiya
Advertisement

Top Categories

Advertisement
socialiya
Advertisement
socialiya
Advertisement
socialiya
Advertisement
socialiya